Humacyte, Inc. (HUMA) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $0.85 (+0.97%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 1, 2025 | Swayampakula Ramakanth | H.C. Wainwright | $3.00 | +252.9% |
| Aug 27, 2025 | Matt Miksic | Barclays | $3.50 | +311.8% |
| Oct 18, 2024 | Matt O'Brien | Piper Sandler | $6.00 | +605.9% |
| Oct 18, 2024 | Ryan Zimmerman | BTIG | $10.00 | +1076.5% |
| Dec 20, 2022 | Cowen Cowen | Cowen & Co. | $5.00 | +488.2% |
| May 15, 2022 | Matt O'Brien | Piper Sandler | $4.00 | +370.6% |
Top Analysts Covering HUMA
HUMA vs Sector & Market
| Metric | HUMA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.04 | 2.24 | 2.41 |
| Analyst Count | 25 | 8 | 18 |
| Target Upside | +252.9% | +1150.0% | +14.9% |
| P/E Ratio | -3.28 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $11M | $11M | $12M | 4 |
| 2027-03-31 | $9M | $11M | $17M | 1 |
| 2027-06-30 | $10M | $13M | $20M | 2 |
| 2027-09-30 | $13M | $17M | $25M | 2 |
| 2027-12-31 | $15M | $20M | $29M | 1 |
| 2028-03-31 | $123M | $159M | $237M | 1 |
| 2028-06-30 | $128M | $166M | $247M | 1 |
| 2028-09-30 | $128M | $166M | $247M | 1 |
| 2028-12-31 | $133M | $172M | $257M | 1 |
| 2029-12-31 | $258M | $440M | $846M | 3 |
| 2030-12-31 | $456M | $780M | $1.50B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.51 | $-0.43 | $-0.38 | 4 |
| 2027-03-31 | $-0.10 | $-0.06 | $-0.05 | 1 |
| 2027-06-30 | $-0.10 | $-0.06 | $-0.04 | 1 |
| 2027-09-30 | $-0.09 | $-0.05 | $-0.04 | 1 |
| 2027-12-31 | $-0.08 | $-0.05 | $-0.03 | 1 |
| 2028-03-31 | $0.35 | $0.50 | $0.82 | 1 |
| 2028-06-30 | $0.37 | $0.53 | $0.86 | 1 |
| 2028-09-30 | $0.36 | $0.51 | $0.84 | 1 |
| 2028-12-31 | $0.37 | $0.52 | $0.85 | 1 |
| 2029-12-31 | $0.58 | $1.26 | $2.78 | 2 |
| 2030-12-31 | $1.15 | $2.50 | $5.49 | 2 |
Frequently Asked Questions
What is the analyst consensus for HUMA?
The consensus among 25 analysts covering Humacyte, Inc. (HUMA) is Buy with an average price target of $4.50.
What is the highest price target for HUMA?
The highest price target for HUMA is $10.00, set by Ryan Zimmerman at BTIG on 2024-10-18.
What is the lowest price target for HUMA?
The lowest price target for HUMA is $3.00, set by Swayampakula Ramakanth at H.C. Wainwright on 2025-12-01.
How many analysts cover HUMA?
25 analysts have issued ratings for Humacyte, Inc. in the past 12 months.
Is HUMA a buy or sell right now?
Based on 25 analyst ratings, HUMA has a consensus rating of Buy (2.04/5) with a +252.9% upside to the consensus target of $4.50.
What are the earnings estimates for HUMA?
Analysts estimate HUMA will report EPS of $-0.43 for the period ending 2026-12-31, with revenue estimated at $11M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.